Idioma:

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology

Schaeffer, Edward M. ; Srinivas, Sandy ; Adra, Nabil ; An, Yi ; Barocas, Daniel ; Bitting, Rhonda ; Bryce, Alan ; Chapin, Brian ; Cheng, Heather H. ; D’Amico, Anthony Victor ; Desai, Neil ; Dorff, Tanya ; Eastham, James A. ; Farrington, Thomas A. ; Gao, Xin ; Gupta, Shilpa ; Guzzo, Thomas ; Ippolito, Joseph E. ; Kuettel, Michael R. ; Lang, Joshua M. ; Lotan, Tamara ; McKay, Rana R. ; Morgan, Todd ; Netto, George ; Pow-Sang, Julio M. ; Reiter, Robert ; Roach, Mack ; Robin, Tyler ; Rosenfeld, Stan ; Shabsigh, Ahmad ; Spratt, Daniel ; Teply, Benjamin A. ; Tward, Jonathan ; Valicenti, Richard ; Wong, Jessica Karen ; Shead, Dorothy A. ; Snedeker, Jenna ; Freedman-Cass, Deborah A.

Journal of the National Comprehensive Cancer Network, 2023-10, Vol.21 (10), p.1067-1096 [Periódico revisado por pares]

Sem texto completo

Citações Citado por

Enviar para

Título:
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Autor: Schaeffer, Edward M. ; Srinivas, Sandy ; Adra, Nabil ; An, Yi ; Barocas, Daniel ; Bitting, Rhonda ; Bryce, Alan ; Chapin, Brian ; Cheng, Heather H. ; D’Amico, Anthony Victor ; Desai, Neil ; Dorff, Tanya ; Eastham, James A. ; Farrington, Thomas A. ; Gao, Xin ; Gupta, Shilpa ; Guzzo, Thomas ; Ippolito, Joseph E. ; Kuettel, Michael R. ; Lang, Joshua M. ; Lotan, Tamara ; McKay, Rana R. ; Morgan, Todd ; Netto, George ; Pow-Sang, Julio M. ; Reiter, Robert ; Roach, Mack ; Robin, Tyler ; Rosenfeld, Stan ; Shabsigh, Ahmad ; Spratt, Daniel ; Teply, Benjamin A. ; Tward, Jonathan ; Valicenti, Richard ; Wong, Jessica Karen ; Shead, Dorothy A. ; Snedeker, Jenna ; Freedman-Cass, Deborah A.
É parte de: Journal of the National Comprehensive Cancer Network, 2023-10, Vol.21 (10), p.1067-1096
Descrição: The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.
Idioma: Inglês

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology

Buscando em bases de dados remotas. Favor aguardar.